The 2022 financial year saw the research and development expenditure of Melbourne-based CSL Limited increase to over 1.1 billion U.S. dollars. CSL Limited is a global biotechnology company that is involved in the research, development, manufacturing, and marketing of products used to treat human medical conditions.
Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars)
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Starter Account
The ideal entry-level account for individual users
- Instant access to 1m statistics
- Download in XLS, PDF & PNG format
- Detailed references
$199 USD / Month *
Professional Account
Full access
Business Solutions including all features.
* Prices do not include sales tax.
Other statistics that may interest you Pharmaceutical industry in Australia
Overview
6
- Basic Statistic Annual revenue of pharmaceutical and cosmetic goods retail Australia 2011-2022
- Premium Statistic Leading pharmaceutical companies listed on ASX Australia 2023
- Premium Statistic Leading biotechnology companies listed on ASX Australia 2023
- Premium Statistic Value of monthly imports of medical and pharmaceutical products Australia 2020-2023
- Premium Statistic Value of monthly exports of medical and pharmaceutical products Australia 2020-2023
- Premium Statistic Subsidized drug expenditure in Australia FY 2016-2022
Prescription medication
6
- Premium Statistic Prevalence of chronic pain Australia 2018 by age group
- Basic Statistic Share of patients who received prescriptions for medication Australia FY 2011-2023
- Basic Statistic Share of prescribed patients Australia FY 2023, by age group and gender
- Premium Statistic Most commonly used prescription drugs Australia FY 2023
- Premium Statistic Most expensive prescription drugs Australia FY 2021, by cost to government
- Premium Statistic Most prescribed prescription drugs Australia FY 2021, by prescriptions
Major Pharmaceuticals
5
- Premium Statistic Total operating revenue of CSL Ltd FY 2015-2022
- Premium Statistic Net profit of CSL Ltd FY 2015-2022
- Premium Statistic R&D expenditure of CSL Ltd FY 2015-2022
- Premium Statistic Revenue of Sonic Healthcare Limited FY 2015-2022
- Premium Statistic EBITDA of Sonic Healthcare Limited FY 2015-2022
Pharmaceutical retailers
7
- Premium Statistic Leading drug stores and pharmaceutical companies Australia 2024, by revenue
- Premium Statistic EBITDA of EBOS Group FY 2016-2022
- Premium Statistic Revenue of EBOS Group FY 2016-2022
- Premium Statistic Revenue of Australian Pharmaceutical Industries Limited 2015-2021
- Premium Statistic EBIT of Australian Pharmaceutical Industries Limited 2015-2021
- Premium Statistic Sales revenue of Sigma Healthcare 2016-2022
- Premium Statistic EBITDA of Sigma Healthcare 2016-2022
Trends
7
- Premium Statistic Sales channel utilization by pharmacies Australia 2022
- Premium Statistic Factors considered when choosing a pharmacy 2021
- Premium Statistic Number of pharmacists in Australia 2022, by registration type
- Premium Statistic Share of online pharmacy sales in Australia 2020, by product type
- Premium Statistic Trusted professions in Australia 2021
- Premium Statistic Most important health professions in Australia 2021
- Premium Statistic Location preferences for health services delivery in Australia 2021
Further related statistics
20
- Total non current assets of CSL Ltd Australia FY 2014-2019
- Total current liabilities of CSL Ltd Australia FY 2014-2019
- Total non current liabilities of CSL Ltd Australia FY 2014-2019
- Total equity of CSL Ltd Australia FY 2014-2019
- Earnings per share of CSL Ltd Australia FY 2015-2019
- Total current assets of CSL Ltd Australia FY 2014-2019
- Leading vaccines and antisera dispensed in England 2022, by item number
- U.S. states which approved specific diseases for treatment with marijuana
- Antimicrobial drug domestic sales for livestock use by drug class U.S. 2020-2022
- Chile: share of elderly people immunized against influenza 2010-2022
- Livestock antimicrobial drugs sales growth in the U.S. by drug class 2012-2021
- Safety and effectiveness of childhood vaccines 2014
- Antimicrobial drugs for livestock total sales U.S. 2009-2022
- Number of drug treatments in Italy in 2022, by ATC
- U.S. adults that believed they personally benefited from vaccines 2018
- Share of drug treatment patients in Norway 2019, by region and gender
- Drug users entering treatment in Turkey 2017, by primary drug
- Drug treatment entrants in Cyprus 2018, by primary drug
- Brazil: hormones imports 2019, by country
- Bolivia: vitamins import value 2017, by country
Further Content: You might find this interesting as well
Statistics
- Total non current assets of CSL Ltd Australia FY 2014-2019
- Total current liabilities of CSL Ltd Australia FY 2014-2019
- Total non current liabilities of CSL Ltd Australia FY 2014-2019
- Total equity of CSL Ltd Australia FY 2014-2019
- Earnings per share of CSL Ltd Australia FY 2015-2019
- Total current assets of CSL Ltd Australia FY 2014-2019
- Leading vaccines and antisera dispensed in England 2022, by item number
- U.S. states which approved specific diseases for treatment with marijuana
- Antimicrobial drug domestic sales for livestock use by drug class U.S. 2020-2022
- Chile: share of elderly people immunized against influenza 2010-2022
- Livestock antimicrobial drugs sales growth in the U.S. by drug class 2012-2021
- Safety and effectiveness of childhood vaccines 2014
- Antimicrobial drugs for livestock total sales U.S. 2009-2022
- Number of drug treatments in Italy in 2022, by ATC
- U.S. adults that believed they personally benefited from vaccines 2018
- Share of drug treatment patients in Norway 2019, by region and gender
- Drug users entering treatment in Turkey 2017, by primary drug
- Drug treatment entrants in Cyprus 2018, by primary drug
- Brazil: hormones imports 2019, by country
- Bolivia: vitamins import value 2017, by country
CSL. (September 2, 2022). Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars) [Graph]. In Statista. Retrieved May 16, 2024, from https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/
CSL. "Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars)." Chart. September 2, 2022. Statista. Accessed May 16, 2024. https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/
CSL. (2022). Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars). Statista. Statista Inc.. Accessed: May 16, 2024. https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/
CSL. "Research and Development Investment of Csl Limited from Financial Year 2015 to 2022 (in Million U.S. Dollars)." Statista, Statista Inc., 2 Sep 2022, https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/
CSL, Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars) Statista, https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/ (last visited May 16, 2024)
Research and development investment of CSL Limited from financial year 2015 to 2022 (in million U.S. dollars) [Graph], CSL, September 2, 2022. [Online]. Available: https://www.statista.com/statistics/1066427/australia-csl-ltd-research-and-development-investment/